According to DelveInsight analysis, the Dystrophic Epidermolysis Bullosa market is expected to witness significant growth between 2024 and 2034 |Major players include Krystal Biotech, Chiesi, Phoenix Therapeutics, Aegle Therapeutics, Anterogen, and others